Defining the Optimal Dose of Rapamycin
This pilot study will determine the dose and schedule of rapamycin, a promising new adjunct cancer drug.
This pilot study will determine the dose and schedule of rapamycin, a promising new adjunct cancer drug.
This study will evaluate dogs with heart disease for a common genetic variant to determine whether this variant affects their ability to respond to heart medications.
This study investigates better postsurgical pain-management strategies for dogs after castration.
This study investigates how cytogenetic changes in canine osteosarcoma affect the duration of disease-free interval when patients are treated with amputation followed by doxorubicin and non-cytotoxic suramin.
This study will provide a molecular framework for understanding the process of miR-9-driven tumor spread in canine osteosarcoma, thereby generating potential new targets for therapy to prevent or treat tumor spread in this devastating disease.
This study evaluates a new therapeutic agent designed to inhibit the survivin protein in canine lymphoma.
This study investigates the role of citrullination in canine mammary cancer and how interfering with this process might lead to more effective anticancer treatments.